ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · IEX Real-Time Price · USD
7.67
-0.41 (-5.07%)
At close: Apr 25, 2024, 4:00 PM
7.68
+0.01 (0.13%)
After-hours: Apr 25, 2024, 6:01 PM EDT
ORIC Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ORIC stock have an average target of 21.33, with a low estimate of 17 and a high estimate of 27. The average target predicts an increase of 178.10% from the current stock price of 7.67.
Analyst Consensus: Buy
* Price targets were last updated on Mar 27, 2024.
Analyst Ratings
The average analyst rating for ORIC stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +134.68% | Mar 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $21 | Strong Buy | Maintains | $15 → $21 | +173.79% | Mar 21, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $17 | Buy | Maintains | $14 → $17 | +121.64% | Mar 12, 2024 |
| Baird | Baird | Buy Reiterates $27 → $25 | Buy | Reiterates | $27 → $25 | +225.95% | Mar 12, 2024 |
| Wedbush | Wedbush | Buy Reiterates $20 | Buy | Reiterates | $20 | +160.76% | Mar 12, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.79
from -1.96
EPS Next Year
-1.99
from -1.79
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 40.1M | 173.1M | 458.5M |
| Avg | n/a | n/a | 15.6M | 84.3M | 445.4M |
| Low | n/a | n/a | n/a | 368,480 | 428.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,006.9% | 444.2% |
| Avg | - | - | - | 438.8% | 428.7% |
| Low | - | - | - | -97.6% | 407.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.74 | -1.62 | -2.07 | -1.81 | 1.34 |
| Avg | -1.79 | -1.99 | -2.36 | -1.90 | 1.31 |
| Low | -1.79 | -2.21 | -2.56 | -1.97 | 1.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.